The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis.
 
Nam Bui
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics
 
Vineet Kwatra
No Relationships to Disclose
 
Christopher W. Ryan
Consulting or Advisory Role - Exelixis
Research Funding - Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline/Novartis (Inst); Karyopharm Therapeutics (Inst); Leducq (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Xynomic Pharma (Inst)
Expert Testimony - Boehringer Ingelheim; GlaxoSmithKline; Pfizer
 
Erlinda Maria Gordon
Stock and Other Ownership Interests - Counterpoint Biomedica; Delta Next-Gene
Research Funding - Jazz Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Co-inventor of patents on targeting pharmaceutical agents to injured tissues
Travel, Accommodations, Expenses - Immix BioPharma
 
Masa Aleckovic
Employment - Shasqi Inc
Stock and Other Ownership Interests - Shasqi Inc.
 
Sangeetha Srinivasan
Employment - Shasqi Inc.
Stock and Other Ownership Interests - Shasqi Inc.
 
Tri-Hung Nguyen
Employment - Shasqi Inc.
 
Jose Manuel Mejia Oneto
Employment - Shasqi Inc.
Leadership - Shasqi Inc.
Stock and Other Ownership Interests - Design Therapeutics; Shasqi Inc.; Tambo; Xencor
Research Funding - SBIR/NCI
Patents, Royalties, Other Intellectual Property - Patent portfolio for Shasqi and TAMBO
 
Esteban Abella-Dominicis
Employment - Shasqi Inc.
Leadership - Remedy Pharmaceuticals
Stock and Other Ownership Interests - Remedy Pharmaceuticals
Consulting or Advisory Role - Remedy Pharmaceuticals
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma